

Anti-TNFRSF5/CD40 Antibody (Selicrelumab)

Introduction

Selicrelumab is a CD40 antibody agonist that can induce changes in the tumor microenvironment. Selicrelumab can be used in pancreatic cancer research and neoadjuvant tumor therapy research.

Product parameters

Alternative Names	RO-7009789, RG-7876
Target Accession	P25942
Target	TNFRSF5 / CD40
CAS number	1622140-49-1
Molecular Weight	146.2 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG2SA
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CD40 His at 2 ug/mL can bind Anti-TNFRSF5/CD40 Antibody (Selicrelumab), EC50=0.009782 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

